Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

This study is comparing two medications — pioglitazone and empagliflozin — to see which is more effective at treating fatty liver disease (excess fat in the liver) in people with type 2 diabetes who are not well controlled on their current medications. **You may be eligible if...** - You are 20 or older - You have type 2 diabetes with HbA1c between 7% and 10% (not well controlled) - You are currently on metformin with a sulfonylurea, a DPP-4 inhibitor, or metformin alone (or triple therapy where a sulfonylurea will be stopped) - You have confirmed fatty liver disease on a liver scan (FibroScan CAP score of 268 or above) - You have at least one metabolic abnormality (e.g., excess belly fat, high blood pressure, or abnormal cholesterol) **You may NOT be eligible if...** - Your blood sugar is too high or too low (outside the 7–10% HbA1c range) - You do not have confirmed fatty liver disease - You do not meet the medication criteria Talk to your doctor to see if this trial is right for you.